Page 12 - Genmark Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: Basel, 22 April 2021 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and GenMark Diagnostics, Inc. today announced that Roche's wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) at a price of USD 24.05 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 21 April 2021 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the ten...

ADVERTISEMENT ADVERTISEMENT GenMark Investor Wants Records On $1.8B Roche Deal Law360 (April 21, 2021, 10:31 PM EDT) -- A GenMark Diagnostics shareholder sued the biotech company Wednesday in Delaware Chancery Court in a bid to gain access to records regarding Roche's planned $1.8 billion acquisition of the disease-testing business, saying there are reasons to suspect the deal was "the result of a potentially conflicted process." The Switzerland-based F. Hoffmann-La Roche Ltd. announced in March that it is buying GenMark and its technology to test for a range of diseases at once. But invest...

Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMa...

Group sales increase 3% 1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales: As expected, significant impact from biosimilars (CHF -1.6 billion) Base effect from the strong first quarter 2020 (negative impact of the pandemic only since April 2020) Overall, this results in a 9% decline in sales. Diagnostics Division sales: Roche's contributions to the fight against the COVID-19 pandemic in the first quarter: SARS-CoV-2 Rapid Antigen Test Nasal to...

Roche Stock Up On Higher Q1 Sales At Constant Rates; Backs FY21 Outlook SOUTH SAN FRANCISCO (dpa-AFX) - Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow in the low- to mid-single digit range, at constant exchange rates, despite the continued stron...